InvestorsHub Logo
Followers 2
Posts 1798
Boards Moderated 0
Alias Born 01/05/2017

Re: hovacre post# 59971

Monday, 03/19/2018 1:19:24 PM

Monday, March 19, 2018 1:19:24 PM

Post# of 108192
" It appeared as though there was reasonable activity for pembro in both PD-L1-positive and -negative patients. "

Listed below is copy and paste of the article:

"None of the 9 PD-L1–negative patients responded to treatment."

Source:
http://www.onclive.com/web-exclusives/fda-grants-pembrolizumab-priority-review-in-cervical-cancer
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News